Axon Enterprise, Inc. (NASDAQ:AXON) President Joshua Isner Sells 1,291 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) President Joshua Isner sold 1,291 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $642.43, for a total transaction of $829,377.13. Following the completion of the sale, the president now owns 181,892 shares in the company, valued at $116,852,877.56. This trade represents a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Joshua Isner also recently made the following trade(s):

• On Tuesday, November 12th, Joshua Isner sold 20,000 shares of Axon Enterprise stock. The shares were sold at an average price of $606.15, for a total transaction of $12,123,000.00.

Axon Enterprise Stock Performance

AXON traded down $13.54 during trading on Tuesday, hitting $635.76. The stock had a trading volume of 1,496,467 shares, compared to its average volume of 581,323. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The firm has a market cap of $48.48 billion, a price-to-earnings ratio of 164.28, a P/E/G ratio of 14.19 and a beta of 1.01. The company has a 50 day moving average price of $548.26 and a 200-day moving average price of $411.38. Axon Enterprise, Inc. has a one year low of $241.72 and a one year high of $698.67.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors and hedge funds have recently modified their holdings of the business. Insigneo Advisory Services LLC grew its position in shares of Axon Enterprise by 1.4% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after purchasing an additional 22 shares in the last quarter. Menard Financial Group LLC increased its stake in Axon Enterprise by 0.8% during the 3rd quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock worth $1,204,000 after acquiring an additional 24 shares during the period. PFG Investments LLC raised its holdings in Axon Enterprise by 0.6% in the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 25 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its position in shares of Axon Enterprise by 1.6% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 26 shares during the period. Finally, Mather Group LLC. grew its holdings in shares of Axon Enterprise by 3.7% during the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 27 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AXON. Northland Securities raised their price objective on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, November 11th. JMP Securities boosted their price target on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 31st. Robert W. Baird increased their price objective on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. Finally, The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $488.67.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.